{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T06:33:21Z","timestamp":1783492401056,"version":"3.55.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,26]],"date-time":"2024-10-26T00:00:00Z","timestamp":1729900800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,10,26]],"date-time":"2024-10-26T00:00:00Z","timestamp":1729900800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Bonn"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background &amp; objectives<\/jats:title>\n                <jats:p>Obesity is a common comorbidity in heart failure, yet effective pharmacological options for weight loss in these patients are limited. Semaglutide, a glucagon-like peptide 1 receptor agonist, has shown promise for weight reduction in obese adults. This study aims to evaluate semaglutide\u2019s impact on weight loss, functional status, and clinical outcomes in obese patients with heart failure.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A retrospective analysis was conducted on all consecutive obese (BMI\u2009&gt;\u200930\u00a0kg\/m\u00b2) patients with heart failure at the University Hospital Bonn outpatient clinic from July 2019 to July 2022. Propensity score matching paired patients receiving semaglutide as an add-on therapy (SEMA) with those on medical therapy alone (Control).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Among 1,942 patients with heart failure screened, 26 matched pairs were identified. At one year, the SEMA group exhibited significant weight loss, with a mean BMI reduction of -2.91\u00a0kg\/m\u00b2 (95% CI: -4.27 to -1.55; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), while the control group showed a non-significant mean change of -0.41\u00a0kg\/m\u00b2 (95% CI: -1.08 to 0.26; <jats:italic>p<\/jats:italic>\u2009=\u20090.22). The difference in BMI between the two groups was statistically significant (mean difference: 3.42\u00a0kg\/m\u00b2, 95% CI: 1.43 to 5.42; <jats:italic>p<\/jats:italic>\u2009=\u20090.001). Improvements by at least one NYHA class were observed in 65% of the SEMA group (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) compared to 15% of the control group (<jats:italic>p<\/jats:italic>\u2009=\u20090.18). The SEMA group also showed a significant increase in 6-minute walk distance (6MWD), with a mean difference of 75\u00a0m between the groups at one year (95% CI: 0.53 to 150.02; <jats:italic>p<\/jats:italic>\u2009=\u20090.049). NT-proBNP levels significantly decreased in the SEMA group (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) compared to the control group (<jats:italic>p<\/jats:italic>\u2009=\u20090.78), with a statistically significant difference in NT-proBNP between the groups (<jats:italic>p<\/jats:italic>\u2009=\u20090.048). Both improvements in 6MWD and reductions in NT-proBNP were significantly correlated with BMI percentage reductions.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Semaglutide was associated with significant weight reduction in obese patients with heart failure, accompanied by improved NYHA classification and 6-minute walk distance. Larger, multi-center trials and prospective, randomized controlled trials are warranted. These studies should focus on assessing long-term outcomes, optimizing dosage, and exploring the potential cardiovascular benefits beyond weight reduction.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12872-024-04275-2","type":"journal-article","created":{"date-parts":[[2024,10,26]],"date-time":"2024-10-26T07:01:43Z","timestamp":1729926103000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Impact of semaglutide on weight and functional outcomes among obese heart failure patients: a propensity scores matching analysis"],"prefix":"10.1186","volume":"24","author":[{"given":"Mahmoud","family":"Balata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc Ulrich","family":"Becher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,26]]},"reference":[{"issue":"4","key":"4275_CR1","doi-asserted-by":"publisher","first-page":"e29","DOI":"10.1161\/CIR.0000000000000152","volume":"131","author":"D Mozaffarian","year":"2015","unstructured":"Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics\u20132015 update: a report from the American Heart Association. Circulation. 2015;131(4):e29\u2013322. https:\/\/doi.org\/10.1161\/CIR.0000000000000152.","journal-title":"Circulation"},{"issue":"12","key":"4275_CR2","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/j.jchf.2016.09.013","volume":"4","author":"E Joyce","year":"2016","unstructured":"Joyce E, Lala A, Stevens SR, et al. Prevalence, Profile, and prognosis of severe obesity in contemporary hospitalized heart failure trial populations. JACC Heart Fail. 2016;4(12):923\u201331. https:\/\/doi.org\/10.1016\/j.jchf.2016.09.013.","journal-title":"JACC Heart Fail"},{"issue":"12","key":"4275_CR3","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1016\/j.amjcard.2011.07.051","volume":"108","author":"TB Horwich","year":"2011","unstructured":"Horwich TB, Broderick S, Chen L, et al. Relation among body mass index, exercise training, and outcomes in chronic systolic heart failure. Am J Cardiol. 2011;108(12):1754\u20139. https:\/\/doi.org\/10.1016\/j.amjcard.2011.07.051.","journal-title":"Am J Cardiol"},{"issue":"22","key":"4275_CR4","doi-asserted-by":"publisher","first-page":"2739","DOI":"10.1016\/j.jacc.2017.09.1111","volume":"70","author":"T Tsujimoto","year":"2017","unstructured":"Tsujimoto T, Kajio H. Abdominal obesity is Associated with an increased risk of all-cause mortality in patients with HFpEF. J Am Coll Cardiol. 2017;70(22):2739\u201349. https:\/\/doi.org\/10.1016\/j.jacc.2017.09.1111.","journal-title":"J Am Coll Cardiol"},{"key":"4275_CR5","doi-asserted-by":"publisher","first-page":"3407306","DOI":"10.1155\/2018\/3407306","volume":"2018","author":"I Csige","year":"2018","unstructured":"Csige I, Ujv\u00e1rosy D, Szab\u00f3 Z, et al. The impact of obesity on the Cardiovascular System. J Diabetes Res. 2018;2018:3407306. https:\/\/doi.org\/10.1155\/2018\/3407306.","journal-title":"J Diabetes Res"},{"issue":"21","key":"4275_CR6","doi-asserted-by":"publisher","first-page":"e984","DOI":"10.1161\/CIR.0000000000000973","volume":"143","author":"TM Powell-Wiley","year":"2021","unstructured":"Powell-Wiley TM, Poirier P, Burke LE, et al. Obesity and Cardiovascular Disease: A Scientific Statement from the American Heart Association. Circulation. 2021;143(21):e984\u20131010. https:\/\/doi.org\/10.1161\/CIR.0000000000000973.","journal-title":"Circulation"},{"key":"4275_CR7","doi-asserted-by":"publisher","DOI":"10.1093\/ehjqcco\/qcab043","author":"D de Bacquer","year":"2021","unstructured":"de Bacquer D, Jennings CS, Mirrakhimov E, et al. Potential for optimizing management of obesity in the secondary prevention of coronary heart disease. Eur Heart J Qual Care Clin Outcomes. 2021. https:\/\/doi.org\/10.1093\/ehjqcco\/qcab043.","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"issue":"1","key":"4275_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1152\/physrev.00023.2021","volume":"102","author":"WK Samson","year":"2022","unstructured":"Samson WK, Yosten GLC, Remme CA. A primer on obesity-related cardiomyopathy. Physiol Rev. 2022;102(1):1\u20136. https:\/\/doi.org\/10.1152\/physrev.00023.2021.","journal-title":"Physiol Rev"},{"issue":"1","key":"4275_CR9","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1001\/jama.2015.17346","volume":"315","author":"DW Kitzman","year":"2016","unstructured":"Kitzman DW, Brubaker P, Morgan T, et al. Effect of Caloric Restriction or Aerobic Exercise Training on Peak Oxygen Consumption and Quality of Life in obese older patients with heart failure with preserved ejection fraction: a Randomized Clinical Trial. JAMA. 2016;315(1):36\u201346. https:\/\/doi.org\/10.1001\/jama.2015.17346.","journal-title":"JAMA"},{"issue":"4","key":"4275_CR10","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/S2213-8587(17)30013-X","volume":"5","author":"C Sorli","year":"2017","unstructured":"Sorli C, Harashima S, Tsoukas GM, et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes Endocrinol. 2017;5(4):251\u201360. https:\/\/doi.org\/10.1016\/S2213-8587(17)30013-X.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"11","key":"4275_CR11","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","volume":"384","author":"JPH Wilding","year":"2021","unstructured":"Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989. https:\/\/doi.org\/10.1056\/NEJMoa2032183.","journal-title":"N Engl J Med"},{"issue":"5","key":"4275_CR12","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1001\/jama.2016.10260","volume":"316","author":"KB Margulies","year":"2016","unstructured":"Margulies KB, Hernandez AF, Redfield MM, et al. Effects of Liraglutide on Clinical Stability among patients with Advanced Heart failure and reduced ejection fraction: a Randomized Clinical Trial. JAMA. 2016;316(5):500\u20138. https:\/\/doi.org\/10.1001\/jama.2016.10260.","journal-title":"JAMA"},{"issue":"1","key":"4275_CR13","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1002\/ejhf.657","volume":"19","author":"A Jorsal","year":"2017","unstructured":"Jorsal A, Kistorp C, Holmager P, et al. Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial. Eur J Heart Fail. 2017;19(1):69\u201377. https:\/\/doi.org\/10.1002\/ejhf.657.","journal-title":"Eur J Heart Fail"},{"issue":"10454","key":"4275_CR14","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/S0140-6736(24)01498-3","volume":"404","author":"J Deanfield","year":"2024","unstructured":"Deanfield J, Verma S, Scirica BM, et al. Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial. Lancet. 2024;404(10454):773\u201386. https:\/\/doi.org\/10.1016\/S0140-6736(24)01498-3.","journal-title":"Lancet"},{"issue":"10437","key":"4275_CR15","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1016\/S0140-6736(24)00469-0","volume":"403","author":"J Butler","year":"2024","unstructured":"Butler J, Shah SJ, Petrie MC, et al. Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials. Lancet. 2024;403(10437):1635\u201348. https:\/\/doi.org\/10.1016\/S0140-6736(24)00469-0.","journal-title":"Lancet"},{"issue":"36","key":"4275_CR16","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599\u2013726. https:\/\/doi.org\/10.1093\/eurheartj\/ehab368.","journal-title":"Eur Heart J"},{"issue":"8","key":"4275_CR17","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1038\/ijo.2013.203","volume":"38","author":"R Padwal","year":"2014","unstructured":"Padwal R, McAlister FA, McMurray JJV, et al. The obesity paradox in heart failure patients with preserved versus reduced ejection fraction: a meta-analysis of individual patient data. Int J Obes (Lond). 2014;38(8):1110\u20134. https:\/\/doi.org\/10.1038\/ijo.2013.203.","journal-title":"Int J Obes (Lond)"},{"issue":"8","key":"4275_CR18","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1016\/j.mayocp.2014.04.025","volume":"89","author":"A de Schutter","year":"2014","unstructured":"de Schutter A, Lavie CJ, Kachur S, Patel DA, Milani RV. Body composition and mortality in a large cohort with preserved ejection fraction: untangling the obesity paradox. Mayo Clin Proc. 2014;89(8):1072\u20139. https:\/\/doi.org\/10.1016\/j.mayocp.2014.04.025.","journal-title":"Mayo Clin Proc"},{"issue":"4","key":"4275_CR19","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1097\/SPC.0b013e32833237f1","volume":"3","author":"LM Freeman","year":"2009","unstructured":"Freeman LM. The pathophysiology of cardiac cachexia. Curr Opin Support Palliat Care. 2009;3(4):276\u201381. https:\/\/doi.org\/10.1097\/SPC.0b013e32833237f1.","journal-title":"Curr Opin Support Palliat Care"},{"issue":"Suppl L","key":"4275_CR20","doi-asserted-by":"publisher","first-page":"L24","DOI":"10.1093\/eurheartj\/suz241","volume":"21","author":"A Lena","year":"2019","unstructured":"Lena A, Ebner N, Anker MS. Cardiac cachexia. Eur Heart J Suppl. 2019;21(Suppl L):L24\u20137. https:\/\/doi.org\/10.1093\/eurheartj\/suz241.","journal-title":"Eur Heart J Suppl"},{"issue":"3","key":"4275_CR21","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1161\/CIRCHEARTFAILURE.108.794099","volume":"2","author":"EB Levitan","year":"2009","unstructured":"Levitan EB, Yang AZ, Wolk A, Mittleman MA. Adiposity and incidence of heart failure hospitalization and mortality: a population-based prospective study. Circ Heart Fail. 2009;2(3):202\u20138. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.108.794099.","journal-title":"Circ Heart Fail"},{"issue":"7","key":"4275_CR22","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1016\/j.amjcard.2013.12.031","volume":"113","author":"MJ Haykowsky","year":"2014","unstructured":"Haykowsky MJ, Kouba EJ, Brubaker PH, Nicklas BJ, Eggebeen J, Kitzman DW. Skeletal muscle composition and its relation to exercise intolerance in older patients with heart failure and preserved ejection fraction. Am J Cardiol. 2014;113(7):1211\u20136. https:\/\/doi.org\/10.1016\/j.amjcard.2013.12.031.","journal-title":"Am J Cardiol"},{"issue":"3","key":"4275_CR23","first-page":"273","volume":"98","author":"FG Romeiro","year":"2012","unstructured":"Romeiro FG, Okoshi K, Zornoff LAM, Okoshi MP. Gastrointestinal changes associated to heart failure. Arq Bras Cardiol. 2012;98(3):273\u20137.","journal-title":"Arq Bras Cardiol"},{"issue":"1","key":"4275_CR24","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.jacc.2024.04.022","volume":"84","author":"MC Petrie","year":"2024","unstructured":"Petrie MC, Borlaug BA, Butler J, et al. Semaglutide and NT-proBNP in obesity-related HFpEF: insights from the STEP-HFpEF program. J Am Coll Cardiol. 2024;84(1):27\u201340. https:\/\/doi.org\/10.1016\/j.jacc.2024.04.022.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"4275_CR25","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.jacc.2024.04.038","volume":"84","author":"M Schou","year":"2024","unstructured":"Schou M, Petrie MC, Borlaug BA, et al. Semaglutide and NYHA Functional Class in obesity-related heart failure with preserved ejection fraction: the STEP-HFpEF program. J Am Coll Cardiol. 2024;84(3):247\u201357. https:\/\/doi.org\/10.1016\/j.jacc.2024.04.038.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"4275_CR26","doi-asserted-by":"publisher","first-page":"145","DOI":"10.2165\/00126839-200708030-00002","volume":"8","author":"C Saraceni","year":"2007","unstructured":"Saraceni C, Broderick TL. Effects of glucagon-like peptide-1 and long-acting analogues on cardiovascular and metabolic function. Drugs R D. 2007;8(3):145\u201353. https:\/\/doi.org\/10.2165\/00126839-200708030-00002.","journal-title":"Drugs R D"},{"issue":"10","key":"4275_CR27","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1007\/s00125-023-05988-3","volume":"66","author":"J Goldney","year":"2023","unstructured":"Goldney J, Sargeant JA, Davies MJ. Incretins and microvascular complications of diabetes: neuropathy, nephropathy, retinopathy and microangiopathy. Diabetologia. 2023;66(10):1832\u201345. https:\/\/doi.org\/10.1007\/s00125-023-05988-3.","journal-title":"Diabetologia"},{"issue":"10","key":"4275_CR28","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1016\/j.jacbts.2023.05.012","volume":"8","author":"C Withaar","year":"2023","unstructured":"Withaar C, Meems LMG, Nollet EE, et al. The cardioprotective effects of Semaglutide Exceed those of Dietary Weight loss in mice with HFpEF. JACC Basic Transl Sci. 2023;8(10):1298\u2013314. https:\/\/doi.org\/10.1016\/j.jacbts.2023.05.012.","journal-title":"JACC Basic Transl Sci"},{"issue":"20","key":"4275_CR29","doi-asserted-by":"publisher","first-page":"3259","DOI":"10.1161\/01.CIR.0000147614.85888.7A","volume":"110","author":"W Verreth","year":"2004","unstructured":"Verreth W, de Keyzer D, Pelat M, et al. Weight-loss-associated induction of peroxisome proliferator-activated receptor-alpha and peroxisome proliferator-activated receptor-gamma correlate with reduced atherosclerosis and improved cardiovascular function in obese insulin-resistant mice. Circulation. 2004;110(20):3259\u201369. https:\/\/doi.org\/10.1161\/01.CIR.0000147614.85888.7A.","journal-title":"Circulation"},{"issue":"1","key":"4275_CR30","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1136\/heartjnl-2019-314770","volume":"106","author":"R Mahajan","year":"2020","unstructured":"Mahajan R, Stokes M, Elliott A, et al. Complex interaction of obesity, intentional weight loss and heart failure: a systematic review and meta-analysis. Heart. 2020;106(1):58\u201368. https:\/\/doi.org\/10.1136\/heartjnl-2019-314770.","journal-title":"Heart"},{"issue":"15","key":"4275_CR31","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with Empagliflozin in Heart failure. N Engl J Med. 2020;383(15):1413\u201324. https:\/\/doi.org\/10.1056\/NEJMoa2022190.","journal-title":"N Engl J Med"},{"issue":"16","key":"4275_CR32","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker SD, Butler J, Filippatos G, et al. Empagliflozin in Heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451\u201361. https:\/\/doi.org\/10.1056\/NEJMoa2107038.","journal-title":"N Engl J Med"},{"issue":"10456","key":"4275_CR33","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/S0140-6736(24)01643-X","volume":"404","author":"MN Kosiborod","year":"2024","unstructured":"Kosiborod MN, Deanfield J, Pratley R, et al. Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials. Lancet. 2024;404(10456):949\u201361. https:\/\/doi.org\/10.1016\/S0140-6736(24)01643-X.","journal-title":"Lancet"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-024-04275-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12872-024-04275-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-024-04275-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,26]],"date-time":"2024-10-26T19:02:46Z","timestamp":1729969366000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccardiovascdisord.biomedcentral.com\/articles\/10.1186\/s12872-024-04275-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,26]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["4275"],"URL":"https:\/\/doi.org\/10.1186\/s12872-024-04275-2","relation":{},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,26]]},"assertion":[{"value":"4 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective study was reviewed and approved by the Ethics Committee at the University of Bonn (reference number 266\/22). Informed consent for the off-label use of semaglutide in treating obesity was obtained from all non-diabetic individuals, or their legal guardians. Our research strictly adhered to relevant guidelines and regulations throughout the entire process.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}}],"article-number":"590"}}